NCT03328273View on ClinicalTrials.gov

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

September 7, 2021

Study Completion Date

August 26, 2026

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Ceralasertib

An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).

DRUG

Acalabrutinib

An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.

Trial Locations (11)

30-510

Research Site, Krakow

93-510

Research Site, Lodz

B9 5SS

Research Site, Birmingham

BH7 7DW

Research Site, Bournemouth

CF14 4XW

Research Site, Cardiff

LS9 7TF

Research Site, Leeds

NW1 2PG

Research Site, London

SE5 9RS

Research Site, London

NG5 1PB

Research Site, Nottingham

OX3 7LJ

Research Site, Oxford

SO16 6YD

Research Site, Southampton

Sponsors

Lead Sponsor

Acerta Pharma BV
All Listed Sponsors
lead

Acerta Pharma BV

INDUSTRY